Eupraxia Pharmaceuticals Cash Flow Statement 2022-2024 | EPRX

Fifteen years of historical annual cash flow statements for Eupraxia Pharmaceuticals (EPRX).

Annual Data | Millions of US $ except per share data

Metric Name
Net Income/Loss
Total Depreciation And Amortization - Cash Flow
Other Non-Cash Items
Total Non-Cash Items
Change In Accounts Receivable
Change In Inventories
Change In Accounts Payable
Change In Assets/Liabilities
Total Change In Assets/Liabilities
Cash Flow From Operating Activities
Net Change In Property, Plant, And Equipment
Net Change In Intangible Assets
Net Acquisitions/Divestitures
Net Change In Short-term Investments
Net Change In Long-Term Investments
Net Change In Investments - Total
Investing Activities - Other
Cash Flow From Investing Activities
Net Long-Term Debt
Net Current Debt
Debt Issuance/Retirement Net - Total
Net Common Equity Issued/Repurchased
Net Total Equity Issued/Repurchased
Total Common And Preferred Stock Dividends Paid
Financial Activities - Other
Cash Flow From Financial Activities
Net Cash Flow
Stock-Based Compensation
Common Stock Dividends Paid
20232022
$-28.97$-18.99
$0.16$0.15
$2.78$2.93
$2.93$3.08
$-0.10$0.23
$0$0
$0$0
$4.88$-0.04
$5.35$1.51
$-20.68$-14.40
$-0.07$-0.24
$0$0
$0$0
$0$10.07
$0$0
$0$10.07
$0$0
$-0.07$9.83
$0$0
$-0.14$-0.14
$-0.14$-0.14
$5.27$0.31
$5.27$0.31
$0$0
$15.89$10.64
$21.01$10.80
$1.08$5.73
$1.41$1.43
$0$0